由于市场价值阈值失效,HCW生物logics面临从Nasdaq公司除名的可能。 HCW Biologics faces potential delisting from Nasdaq due to failing market value thresholds.

一家生物制药公司HCW Biologics Inc.未能达到Nasdaq对其上市证券市场价值5 000万美元的门槛值,从而可能导致除名。 HCW Biologics Inc., a biopharmaceutical company, has failed to meet Nasdaq's $50 million threshold for the market value of its listed securities, leading to a potential delisting. 该公司收到通知,并计划请求举行听证会,对该决定提出上诉,并寻求延期,以恢复合规。 The company received a notice and is planning to request a hearing to appeal the decision and seek an extension to regain compliance. HCW Biologics的股票价格在新闻报道后下跌13.1%至39美分。 HCW Biologics' stock price dropped by 13.1% to 39 cents following the news.